Norditropin Human Growth Hormone Launched in the U.S.
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




Norditropin Human Growth Hormone Launched in the U.S.

NEW YORK-- Feb. 20, 1997-- Norditropin(R) (somatropin (rDNA origin) for injection), indicated for the long-term treatment of children who have growth failure due to inadequate secretion of endogenous (pituitary gland produced) growth hormone is now available in the U.S.

Lars Barfod, vice president, marketing and business development, Novo Nordisk Pharmaceuticals Inc., said, "We are pleased to introduce Norditropin(R) to the U.S. market. Norditropin(R) has been available in 66 countries worldwide since 1988, and has been used with success by more than 30,000 children." He added, "This product launch marks another goal reached by Novo Nordisk in our dedication and commitment to serving the needs of those with endocrine disorders in the US."

Wayman Wendell Cheatham, MD, medical director, Novo Nordisk Pharmaceuticals Inc., said, "Human growth hormone is responsible for stimulating normal skeletal, connective tissue, muscle and organ growth in children and adolescents. It is also active in normal protein, carbohydrate and fat metabolism." He added, "If the amount of growth hormone production by the body is insufficient, short stature, reduced muscle and soft tissue mass and altered nutrient metabolism result. Such problems significantly impact an individual's physical function throughout life, if not treated appropriately. Therapy with Norditropin(R) around the world has been highly successful in reducing such effects in children and adolescents diagnosed with growth hormone insufficiency by maintaining appropriate growth and development to maturity."

Novo Nordisk A/S is the world leader in insulin and diabetes care and also manufactures and markets a variety of other pharmaceutical products. Furthermore, the company is the world's largest producer of industrial enzymes.

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities